News

Immunetune Announces Presentations at Industry Conferences during April and May 2022 LEIDEN, the Netherlands, April 20, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the...

Sachs 15th Annual European Life Science CEO Forum February 28 - March 4, Digital Conference

Immunetune Publishes Preclinical Data on Novel Adjuvant in the Journal Vaccine   LEIDEN, the Netherlands, February 23, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, announced today...

Sachs 15th Annual European Life Science CEO Forum February 28 - March 4, Digital Conference

Immunetune Publishes Preclinical Data on Novel Adjuvant in the Journal Vaccine   LEIDEN, the Netherlands, February 23, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, announced today...

Immunetune Appoints Paul van der Horst and Johan Devenyns to its Supervisory Board LEIDEN, the Netherlands, January 25, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the...

Immunetune Establishes International Scientific Advisory Board LEIDEN, the Netherlands, January 11, 2022 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the appointment of...